Sugi Predict

Sugi Predict / Targets / PNP

PNP

Purine nucleoside phosphorylase · P00491 · PNP on Sugi Atlas →

29,088 patent compounds predicted against PNP, 17,075 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
Ulodesine Ulodesine (SCHEMBL474735) 1.00 18/20
SCHEMBL18249 SCHEMBL18249 1.00 17/20
SCHEMBL505891 SCHEMBL505891 0.65 16/20
SCHEMBL505433 SCHEMBL505433 0.62 16/20
SCHEMBL506019 SCHEMBL506019 0.60 14/20
SCHEMBL505834 SCHEMBL505834 0.55 14/20
SCHEMBL505570 SCHEMBL505570 0.65 13/20
SCHEMBL505960 SCHEMBL505960 0.54 12/20
SCHEMBL489056 SCHEMBL489056 0.70 11/20
Hydrochloric Acid Hydrochloric Acid (SCHEMBL258897) 0.69 11/20
Trifluoroacetic Acid Trifluoroacetic Acid (SCHEMBL631061) 0.59 11/20
Acyclovir Acyclovir (SCHEMBL3175) 1.00 10/20
SCHEMBL18248 SCHEMBL18248 1.00 10/20
Acyclovir Acyclovir (SCHEMBL40724) 0.97 10/20
Forodesine Forodesine (SCHEMBL506383) 0.75 10/20
SCHEMBL571645 SCHEMBL571645 0.72 10/20
SCHEMBL505709 SCHEMBL505709 0.64 10/20
SCHEMBL505326 SCHEMBL505326 0.56 10/20
SCHEMBL146427 SCHEMBL146427 0.50 10/20
SCHEMBL554861 SCHEMBL554861 0.42 10/20

Clinical trials — most relevant to PNP by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
ONCE - Only Nocturnal Combination Evaluation of Antiretroviral-Experienced HIV 1 Infected Subjects Switching to Atripla PHASE4COMPLETED
Study To Evaluate Long Term Maintenance With TRIZIVIR After Boosted Protease Inhibitor (PI) Or Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI) In HIV-1 Infected Adults PHASE4COMPLETED
Acelarin First Line Randomised Pancreatic Study PHASE2/PHASE3SUSPENDED
Tenofovir Disoproxil Fumarate/Emtricitabine/Efavirenz Versus Combivir/Efavirenz in Antiretroviral-Naive HIV-1 Infected Subjects PHASE3COMPLETED
A RCT of TNF and ENT in the Treatment of Long-term Prognosis With Hepatitis B-related HCC After Curative Resection PHASE3UNKNOWN
Evaluation of Compliance With Treatment by Genvoya in HIV Post-exposure Prophylaxis PHASE3COMPLETED
A Randomized Pilot Study for the Treatment of AIDS or AIDS Related Complex With an Alternating or Simultaneous Combination Regimen of AZT and 2',3'-Dideoxyinosine PHASE3COMPLETED
Safety and Efficacy of Repeat Administration of Ad/PNP and Fludarabine Phosphate in Patients With Local Head/Neck Cancer PHASE1/PHASE2COMPLETED
Phase II Study of Ribose, Uridine, and Thymidine for a Complex Syndrome Involving Excessive 5'-Nucleotidase Activity PHASE2COMPLETED
A Pilot Study of Pre-Exposure Prophylaxis (PrEP) to Evaluate Safety, Acceptability, and Adherence in At-Risk Populations in Kenya, Africa PHASE1/PHASE2COMPLETED
A Pilot Study of Pre-Exposure Prophylaxis (PrEP) to Evaluate Safety, Acceptability, and Adherence in At-risk Populations in Uganda, Africa PHASE1/PHASE2COMPLETED
Safety, Tolerance, Pharmacokinetic and Antiviral Study of Amdoxovir in Combination With Zidovudine in Adults With HIV PHASE1/PHASE2COMPLETED
A Phase II Study of Capecitabine and Docetaxel in Previously Untreated Advanced Non-Small Cell Lung Cancer Patients PHASE2COMPLETED
Extended Safety Study of Tenofovir Disoproxil Fumarate (TDF) Among HIV-1 Negative Men PHASE2COMPLETED
10-Propargyl-10-Deazaaminopterin in Treating Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma or Hodgkin's Lymphoma PHASE1/PHASE2COMPLETED
BAY43-9006 - Phase II in Advanced Breast Cancer PHASE2COMPLETED
Belotecan Versus Topotecan for Recurrent Ovarian Cancer: A Randomized, Open-label, Parallel-group Phase IIb Trial PHASE2COMPLETED
Antiviral Therapy in Treating Patients With Slowly Progressing HIV-Related Kaposi's Sarcoma PHASE2UNKNOWN
Viral Dynamics and Pharmacokinetics of Abacavir and Tenofovir PHASE2COMPLETED
Oral Thalidomide and Tegafur-uracil to Decrease Hepatocellular Carcinoma Recurrence PHASE2COMPLETED
Nab-paclitaxel (Abraxane), Gemcitabine, and Capecitabine (Xeloda) for Pancreatic Adenocarcinoma PHASE1COMPLETED
Intrapleural AdV-tk Therapy in Patients With Malignant Pleural Effusion PHASE1COMPLETED
Irinotecan and Capecitabine in Treating Patients With Solid Tumors PHASE1COMPLETED
Prevalence of Adenosine Deaminase (ADA) Enzyme Deficiency Disease in Adult Patients With Pulmonary Alveolar Proteinosis nanUNKNOWN
Investigation of ADA Enzyme Deficiency nanUNKNOWN
A RETROspective Study of Patients With TK2d nanCOMPLETED
Evaluation of Adenosine Deaminase (ADA) Enzyme Deficiency in Patients With Lymphopenia and/or Elevated Immunoglobulin E nanUNKNOWN
Standard Antiretroviral v. Multi-class Therapy in Acutely HIV-1 Infected Antiretroviral-Naïve Subjects (ADARC 2007-01) nanCOMPLETED
Implementation and Quality Assurance of DPYD-genotyping in Patients Treated With Fluoropyrimidines. nanCOMPLETED
Observational Study Evaluating the Prevalence of Enzyme Deficiency in Pulmonology Clinics (ADA) nanUNKNOWN

Related proteins — ESM-2 sequence neighbours (a PNP binder may also engage these)

ProteinNameSimilarity
P85973 — 1.000 P85973 →
P23492 — 1.000 P23492 →
P55859 — 1.000 P55859 →
P77834 — 0.993 P77834 →
P45563 — 0.990 P45563 →
P46354 — 0.988 P46354 →
P0DJF9 — 0.983 P0DJF9 →
Q05788 — 0.979 Q05788 →
C1F1E7 — 0.978 C1F1E7 →
Q87BR7 — 0.978 Q87BR7 →
Q87ZC3 — 0.978 Q87ZC3 →
Q8YMD9 — 0.978 Q8YMD9 →
A8NEP3 — 0.978 A8NEP3 →
B0JU82 — 0.978 B0JU82 →
Q89VT5 — 0.977 Q89VT5 →
P0DJF8 — 0.977 P0DJF8 →
B0BU72 — 0.977 B0BU72 →
P13228 — 0.977 P13228 →
Q5KZ06 — 0.977 Q5KZ06 →
Q1GXH3 — 0.977 Q1GXH3 →
Q1DDB7 — 0.977 Q1DDB7 →
Q3AGF7 — 0.977 Q3AGF7 →
Q9KLL6 — 0.977 Q9KLL6 →
Q8D737 — 0.977 Q8D737 →
P77187 — 0.976 P77187 →
B3GX46 — 0.976 B3GX46 →
Q31JD2 — 0.976 Q31JD2 →
A0KVD1 — 0.976 A0KVD1 →
Q09816 — 0.976 Q09816 →
A9WAL0 — 0.976 A9WAL0 →